{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:11:50Z","timestamp":1777961510675,"version":"3.51.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>High-risk localized prostate cancer is often associated with a higher risk of disease progression post-surgery. While radical prostatectomy (RP) is a cornerstone treatment, neoadjuvant chemohormonal therapy (CHT) combining docetaxel plus androgen deprivation therapy (ADT) prior to RP has shown promising efficacy in improving survival outcomes. This study aimed to evaluate the economic efficacy of neoadjuvant CHT followed by RP based on the results of CALGB 90203 from the perspective of Chinese healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partitioned survival model with three states: event-free survival (EFS), progressive disease (PD), and death, was constructed. Clinical efficacy data, including overall survival and event-free survival, were obtained from the CALGB 90203 trial. Utility values, costs of drugs, surgery, follow-up, and adverse events were derived from local data and literature. Lifetime costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) of neoadjuvant therapy vs. surgery alone per QALY gained were calculated, with a 5% annual discount rate applied. Cost-effectiveness was assessed against a willingness-to-pay (WTP) threshold of $41,859 per QALY. One-way and probabilistic sensitivity analyses were conducted to test model robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with RP alone, the neoadjuvant CHT strategy provided an additional 1.08 QALYs at an incremental cost of $5,663, resulting in an ICER of $5,238 per QALY. The model was most sensitive to changes in health utility values of EFS and PD state. Probabilistic sensitivity analysis indicated a 96.40% probability that neoadjuvant CHT is cost-effective at the defined threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From the Chinese payer's perspective, neoadjuvant CHT prior to radical prostatectomy is a highly cost-effective treatment strategy for patients with high-risk localized prostate cancer even when accounting for the upfront costs and quality-of-life impact associated with treatment-related adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1786699","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:32:03Z","timestamp":1777959123000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of neoadjuvant docetaxel plus androgen deprivation therapy before radical prostatectomy in high-risk localized prostate cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Qi","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenling","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junru","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyuan","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengran","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/JCO.2010.31.4252","article-title":"Outcomes of active surveillance for men with intermediate-risk prostate cancer","volume":"29","author":"Cooperberg","year":"2011","journal-title":"J Clin Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"Sweeney","year":"2016","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.juro.2007.03.105","article-title":"Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods","volume":"178","author":"Yossepowitch","year":"2007","journal-title":"J Urol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0022-5347(05)65971-X","article-title":"Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects","volume":"166","author":"Gleave","year":"2001","journal-title":"J Urol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"Systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1200\/jco.2014.32.15_suppl.e16010","article-title":"Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of a US claims database","volume":"14","author":"Flaig","year":"2014","journal-title":"BMC Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","author":"Porter","year":"2010","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010099","article-title":"Current status of neoadjuvant treatment before surgery in high-risk localized prostate cancer","author":"G\u00f3mez Rivas","year":"2024","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(19)32136-1","article-title":"10 years of health-care reform in China: progress and gaps in Universal Health Coverage","volume":"394","author":"Yip","year":"2019","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev-publhealth-031816-044247","article-title":"China's health reform update","volume":"38","author":"Liu","year":"2017","journal-title":"Annu Rev Public Health."},{"key":"B20","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/jnci\/90.10.766","article-title":"A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer","volume":"90","author":"Kattan","year":"1998","journal-title":"J Natl Cancer Inst."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.11.020","article-title":"Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer","year":"2015","journal-title":"Urol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"17588359221116604","DOI":"10.1177\/17588359221116604","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma","volume":"14","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"eGS4414","DOI":"10.31744\/einstein_journal\/2019GS4414","article-title":"Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer","volume":"17","author":"Aguiar","year":"2019","journal-title":"Einstein"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","author":"Sathianathen","year":"2021","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.3390\/cancers17132258","article-title":"Treatment intensification prior to radical prostatectomy for clinically localized prostate cancer","volume":"17","author":"Perez","year":"2025","journal-title":"Cancers."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.04.012","article-title":"Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer","year":"2008","journal-title":"J Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.01.015","article-title":"Long-term outcomes and prognostic impact of residual cancer burden after intensified neoadjuvant therapy in high-risk prostate cancer","author":"Ravi","year":"2025","journal-title":"Eur Urol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"153933","DOI":"10.1016\/j.prp.2022.153933","article-title":"Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations","volume":"234","author":"Zhang","year":"2022","journal-title":"Pathology-Research and Practice"},{"key":"B29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes."},{"key":"B30","doi-asserted-by":"publisher","first-page":"17562872251414928","DOI":"10.1177\/17562872251414928","article-title":"Cost-effectiveness of novel antiandrogens for the treatment of nmCRPC patients in the Chinese healthcare system","volume":"18","author":"Yang","year":"2026","journal-title":"Ther Adv Urol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.euros.2025.12.005","article-title":"Mapping of QLQ-C30 and QLQ-PR25 Scores to EQ-5D-5L Utility Values for Patients with Prostate Cancer Receiving Novel Androgen Receptor Signaling Inhibitors","volume":"83","author":"Hao","year":"2026","journal-title":"European Urology Open Science."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA."},{"key":"B33","doi-asserted-by":"publisher","author":"Briggs","year":"2006","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"B34","doi-asserted-by":"publisher","first-page":"608375","DOI":"10.3389\/fpubh.2021.608375","article-title":"Adding enzalutamide to first-line treatment for metastatic hormone-sensitive prostate cancer: a cost-effectiveness analysis","volume":"9","year":"2021","journal-title":"Front Public Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12962-019-0193-4","article-title":"Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis","volume":"17","author":"Hu","year":"2019","journal-title":"Cost Eff Resour Allocn"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: an international study","volume":"13","author":"Nafees","year":"2017","journal-title":"Asia Pac J Clin Oncol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1786699\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:32:04Z","timestamp":1777959124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1786699\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":36,"alternative-id":["10.3389\/fpubh.2026.1786699"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1786699","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"article-number":"1786699"}}